Welcome to ORVEX biomedical research.
Welcome to ORVEX biomedical research.
Research Area:
Regenerative Research
Product Description:
This is a synthetic peptide combination supplied in lyophilized powder form for use in qualified laboratory environments. BPC-157 and TB-500 are research compounds investigated in preclinical models involving tissue repair, angiogenesis, endothelial cell activity, cell migration, and related biological pathways. This material is intended exclusively for in vitro, analytical, and non-clinical research applications under controlled laboratory conditions. It has not been evaluated or approved for clinical, therapeutic, diagnostic, human, or veterinary use.
Product Designation Note:
This product is identified as BPC-157 + TB-500 for internal cataloging and research differentiation purposes. The combination is supplied as research material and is not marketed, labeled, or represented as a pharmaceutical product for human or veterinary administration.
Research Applications:
In controlled laboratory research settings, this peptide combination may be utilized to support investigation of:
Angiogenesis and vascular signaling pathways
Endothelial cell migration and vascular sprouting
Tissue repair and wound-healing mechanisms
Cell migration and cytoskeletal dynamics
Nitric oxide-associated signaling pathways
VEGF- and angiogenesis-related cellular responses
Extracellular matrix and tissue-remodeling processes
Comparative investigation of peptide-mediated biological activity
Peptide structure, integrity, degradation, and stability
In vitro assay development and analytical characterization
All research activities are conducted exclusively in non-human, non-clinical experimental models.
Mechanistic Research Context:
BPC-157 has been investigated in preclinical models for its effects on angiogenesis, vascular responses, and tissue repair. Experimental studies have associated its activity with pathways involving VEGF, nitric oxide signaling, and vascular response mechanisms.
TB-500 is associated with the actin-binding region of thymosin beta-4 and is investigated in relation to actin dynamics, endothelial cell migration, angiogenesis, and tissue-repair processes.
The available evidence for these mechanisms is predominantly derived from in vitro and animal studies. The biological activity of the combination should therefore be considered investigational and not established as a clinical effect in humans.
Storage and Handling:
Store the lyophilized powder under appropriate laboratory storage conditions in accordance with validated stability requirements and supplier specifications.
Maintain controlled environmental conditions and protect the material from excessive heat, moisture, and direct light.
Once prepared for analytical testing, handle and store the material according to validated laboratory protocols appropriate for the specific assay or experimental system.
Maintain appropriate laboratory and aseptic handling practices where required.
Product Specifications:
Purity: ≥99% (HPLC Certified), where applicable to the supplied batch
Appearance: Lyophilized white powder
Form: Synthetic peptide combination
Application: In vitro and analytical research only
Solubility: Soluble in suitable laboratory agents, subject to formulation and experimental conditions
Research Status:
The available scientific literature concerning BPC-157 and TB-500 is predominantly preclinical, including cellular and animal research. Published research has investigated pathways associated with angiogenesis, tissue repair, endothelial activity, and cell migration. No established clinical efficacy or safety profile for the BPC-157 + TB-500 combination has been established.
Compliance Notice:
This compound combination is FOR RESEARCH USE ONLY and is supplied as an analytical research material. BPC-157 and TB-500 are investigational research compounds studied primarily in preclinical experimental systems.
This research material is not intended for human or veterinary use, is not supplied as a pharmaceutical drug product, and has not been evaluated or approved for clinical administration. It must not be represented, promoted, or used as a medicinal product.
Misuse, unauthorized administration, or use outside controlled research environments is strictly prohibited and may violate applicable federal, state, or local laws.
By purchasing this product, the buyer represents and warrants that the material will be used exclusively for legitimate in vitro, analytical, and non-clinical research purposes by appropriately qualified personnel.
$76.00
Research Area:
Regenerative Research
Product Description:
This is a synthetic peptide combination supplied in lyophilized powder form for use in qualified laboratory environments. BPC-157 and TB-500 are research compounds investigated in preclinical models involving tissue repair, angiogenesis, endothelial cell activity, cell migration, and related biological pathways. This material is intended exclusively for in vitro, analytical, and non-clinical research applications under controlled laboratory conditions. It has not been evaluated or approved for clinical, therapeutic, diagnostic, human, or veterinary use.
Product Designation Note:
This product is identified as BPC-157 + TB-500 for internal cataloging and research differentiation purposes. The combination is supplied as research material and is not marketed, labeled, or represented as a pharmaceutical product for human or veterinary administration.
Research Applications:
In controlled laboratory research settings, this peptide combination may be utilized to support investigation of:
Angiogenesis and vascular signaling pathways
Endothelial cell migration and vascular sprouting
Tissue repair and wound-healing mechanisms
Cell migration and cytoskeletal dynamics
Nitric oxide-associated signaling pathways
VEGF- and angiogenesis-related cellular responses
Extracellular matrix and tissue-remodeling processes
Comparative investigation of peptide-mediated biological activity
Peptide structure, integrity, degradation, and stability
In vitro assay development and analytical characterization
All research activities are conducted exclusively in non-human, non-clinical experimental models.
Mechanistic Research Context:
BPC-157 has been investigated in preclinical models for its effects on angiogenesis, vascular responses, and tissue repair. Experimental studies have associated its activity with pathways involving VEGF, nitric oxide signaling, and vascular response mechanisms.
TB-500 is associated with the actin-binding region of thymosin beta-4 and is investigated in relation to actin dynamics, endothelial cell migration, angiogenesis, and tissue-repair processes.
The available evidence for these mechanisms is predominantly derived from in vitro and animal studies. The biological activity of the combination should therefore be considered investigational and not established as a clinical effect in humans.
Storage and Handling:
Store the lyophilized powder under appropriate laboratory storage conditions in accordance with validated stability requirements and supplier specifications.
Maintain controlled environmental conditions and protect the material from excessive heat, moisture, and direct light.
Once prepared for analytical testing, handle and store the material according to validated laboratory protocols appropriate for the specific assay or experimental system.
Maintain appropriate laboratory and aseptic handling practices where required.
Product Specifications:
Purity: ≥99% (HPLC Certified), where applicable to the supplied batch
Appearance: Lyophilized white powder
Form: Synthetic peptide combination
Application: In vitro and analytical research only
Solubility: Soluble in suitable laboratory agents, subject to formulation and experimental conditions
Research Status:
The available scientific literature concerning BPC-157 and TB-500 is predominantly preclinical, including cellular and animal research. Published research has investigated pathways associated with angiogenesis, tissue repair, endothelial activity, and cell migration. No established clinical efficacy or safety profile for the BPC-157 + TB-500 combination has been established.
Compliance Notice:
This compound combination is FOR RESEARCH USE ONLY and is supplied as an analytical research material. BPC-157 and TB-500 are investigational research compounds studied primarily in preclinical experimental systems.
This research material is not intended for human or veterinary use, is not supplied as a pharmaceutical drug product, and has not been evaluated or approved for clinical administration. It must not be represented, promoted, or used as a medicinal product.
Misuse, unauthorized administration, or use outside controlled research environments is strictly prohibited and may violate applicable federal, state, or local laws.
By purchasing this product, the buyer represents and warrants that the material will be used exclusively for legitimate in vitro, analytical, and non-clinical research purposes by appropriately qualified personnel.
Orvexbio Research Transparency is essential. Every batch undergoes independent third-party testing in the USA, with Certificates of Analysis (COAs) readily available for verification, providing researchers with confidence in the quality and consistency of their work.
